Related Experiment Video

Updated: Mar 1, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.6K

Determinants of levothyroxine dose required to achieve euthyroidism in pediatric population-a hospital-based

Rekha Singh1

  • 1Department of Endocrinology, Nizam's Institute of Medical Sciences, Hyderabad, 500082, India. rekha.endo@gmail.com.

European Journal of Pediatrics
|June 5, 2017
PubMed

Insights

Pretreatment height and serum TSH levels can predict the accurate levothyroxine dose for children with acquired primary hypothyroidism. This helps achieve euthyroidism more effectively than age-based dosing.

Area of Science:

  • Pediatric Endocrinology
  • Thyroid Disorders
  • Pharmacokinetics

Background:

  • Accurate levothyroxine (LT4) dosing is crucial for managing acquired primary hypothyroidism in children.
  • Current LT4 dose recommendations are primarily based on age, which may not be optimal for all pediatric patients.
  • Individualizing LT4 dosage requires understanding factors influencing metabolic requirements.

Purpose of the Study:

  • To investigate the relationship between pretreatment anthropometric measures and serum thyrotropin (TSH) levels with levothyroxine requirements in children.
  • To identify predictors for determining the optimal levothyroxine dose in newly diagnosed pediatric hypothyroidism.
  • To compare the efficacy of anthropometric and TSH-based dosing versus age-based dosing.

Main Methods:

  • Prospective analysis of 51 children (3-18 years) with newly diagnosed acquired primary hypothyroidism.
  • Levothyroxine dose adjustment to achieve euthyroidism (serum TSH 0.4-4.5 mIU/L).
  • Univariate and multivariate regression analyses to correlate age, gender, height, weight, and serum TSH with levothyroxine dose (per weight and per BSA).

Main Results:

  • Age, weight, height, and pretreatment serum TSH significantly correlated with levothyroxine daily dose (D/W and D/BSA).
  • Log10 TSH and gender explained approximately 60% of the absolute levothyroxine daily requirement.
  • A final model incorporating height and serum TSH predicted ~85% of D/W and ~80% of D/BSA.

Conclusions:

  • Pretreatment height and serum TSH are reliable indicators for determining the levothyroxine dose in children with newly diagnosed acquired primary hypothyroidism.
  • Pretreatment height explains the effect of age on levothyroxine daily dose requirements in the pediatric population.
  • Serum TSH level is a key predictor of levothyroxine dose needed to achieve euthyroidism in children.

Keywords:
Levothyroxine dosePediatricPretreatment heightSerum TSH

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.6K
Author Spotlight: Accurately Assessing Thyroid Hormone-Driven Motor Alterations in Mouse04:05

Author Spotlight: Accurately Assessing Thyroid Hormone-Driven Motor Alterations in Mouse

Published on: October 6, 2023

818

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
434
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
338
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
301
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
387
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
392
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
192